Free Image
The Teva Pharmaceutical Industries Ltd. company announced on March 11 that as part of a restructuring of its global production network it intended to find a new strategic partner to handle production at the Zdravlje pharmaceutical factory with which it will continue developing the factory’s business operations.
In a statement on that, Teva – a multinational corporation seated in Israel and the U.S., said that its decision was based on its needs and that “it is not in any case based on any deficiencies or problems regarding business performance or quality standards as they apply to the Zdravlje factory and its employees.”
It added that, alongside this new strategic partner, it would arrange “the continuation of the production of a portion of Teva’s drug portfolio for the next two to three years, so as to ensure that they is enough time for everyone to adjust to the new circumstances.” Zdravlje joined Teva in 2016 when Teva acquired the Aktavis company. Zdravlje, one of the most technologically advanced factories of its kind in the Balkans, exports most of what it makes.
The factory is also one of the biggest suppliers of the domestic drug market and one of Serbia’s biggest exporters. Zdravlje products are sold in Serbia, neighboring states and 40 countries around the world.
The Leskovac factory has been one of the first pharmaceutical companies in Serbia to adopt “the highest domestic and European standards as well global good manufacturing practices (GMP) which guarantees quality, efficiency and the safety of drugs in accordance with the highest standards,” a statement said.
To get full access to all content of interest see our
Subscription offer
Or
Register for free
And read up to 5 articles each month.
Already have an account? Please Log in.